NASDAQ:COCP Cocrystal Pharma (COCP) Stock Price, News & Analysis $1.00 +0.02 (+2.43%) Closing price 04:00 PM EasternExtended Trading$0.98 -0.02 (-1.61%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cocrystal Pharma Stock (NASDAQ:COCP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cocrystal Pharma alerts:Sign Up Key Stats Today's Range$0.95▼$1.0050-Day Range$0.95▼$1.5752-Week Range$0.86▼$2.67Volume73,263 shsAverage Volume1.35 million shsMarket Capitalization$13.72 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Cocrystal Pharma, Inc. (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development. The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections. Lead projects target influenza A and B polymerases as well as key enzymes in coronaviruses such as SARS-CoV-2. Additional research efforts are directed at antiviral targets in hepatitis B virus, norovirus and other emerging viral threats, reflecting Cocrystal’s commitment to addressing a broad spectrum of infectious diseases. Founded in 2006 and headquartered in Bothell, Washington, Cocrystal Pharma leverages collaborations with academic institutions and contract research organizations to expand its drug discovery capabilities. The company maintains research laboratories in the Seattle area and operates a business development office in New York City to engage with strategic partners and investors globally. Under the leadership of founder and Chief Executive Officer Kenneth T. Hitchcock, Ph.D., Cocrystal Pharma seeks to address unmet medical needs in antiviral therapy. By combining deep structural biology expertise with a scalable discovery engine, the company aims to advance novel antivirals poised to combat both seasonal outbreaks and future pandemic threats.AI Generated. May Contain Errors. Read More Cocrystal Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreCOCP MarketRank™: Cocrystal Pharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 526th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCocrystal Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCocrystal Pharma has a consensus price target of $6.00, representing about 503.0% upside from its current price of $1.00.Amount of Analyst CoverageCocrystal Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Cocrystal Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cocrystal Pharma are expected to grow in the coming year, from ($0.69) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cocrystal Pharma is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cocrystal Pharma is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCocrystal Pharma has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cocrystal Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.71% of the float of Cocrystal Pharma has been sold short.Short Interest Ratio / Days to CoverCocrystal Pharma has a short interest ratio ("days to cover") of 1.09, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cocrystal Pharma has recently decreased by 25.70%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCocrystal Pharma does not currently pay a dividend.Dividend GrowthCocrystal Pharma does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for COCP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cocrystal Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders39.40% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions6.72% of the stock of Cocrystal Pharma is held by institutions.Read more about Cocrystal Pharma's insider trading history. Receive COCP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COCP Stock News HeadlinesCocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive OfficerJune 3, 2026 | globenewswire.comCOCP: Presentation highlights CDI-988June 1, 2026 | msn.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.June 18 at 1:00 AM | Porter & Company (Ad)Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and InfluenzaMay 26, 2026 | globenewswire.comCocrystal Pharma IncMay 17, 2026 | edition.cnn.comCocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comCocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus InfectionApril 30, 2026 | globenewswire.comCocrystal Pharma (COCP) price target increased by 33.33% to 8.16April 16, 2026 | msn.comSee More Headlines COCP Stock Analysis - Frequently Asked Questions How have COCP shares performed this year? Cocrystal Pharma's stock was trading at $0.9790 at the beginning of 2026. Since then, COCP stock has increased by 1.6% and is now trading at $0.9950. How were Cocrystal Pharma's earnings last quarter? Cocrystal Pharma, Inc. (NASDAQ:COCP) released its earnings results on Friday, May, 15th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.02. The company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.23 million. When did Cocrystal Pharma's stock split? Cocrystal Pharma shares reverse split on the morning of Tuesday, October 11th 2022.The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Cocrystal Pharma? Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cocrystal Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cocrystal Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), OPKO Health (OPK), Advanced Micro Devices (AMD), NIO (NIO), CrowdStrike (CRWD) and Pfizer (PFE). Company Calendar Last Earnings5/15/2026Today6/18/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 2 weeks, COCP's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COCP CIK1412486 Webwww.cocrystalpharma.com Phone(305) 425-1780FaxN/AEmployees10Year Founded2004Price Target and Rating Average Price Target for Cocrystal Pharma$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside+503.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.83 million Net MarginsN/A Pretax Margin-3,924.00% Return on Equity-150.61% Return on Assets-97.86% Debt Debt-to-Equity RatioN/A Current Ratio2.66 Quick Ratio2.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book2.16Miscellaneous Outstanding Shares13,790,000Free Float8,355,000Market Cap$13.72 million OptionableNot Optionable Beta1.42 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:COCP) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredChina can’t stop buying gold. Here’s why that mattersChina has made 18 consecutive months of central bank gold purchases - and analysts believe the official number...Traders Agency | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredHopeless About Retirement? Hopeless and Helpless Aren’t the Same ThingYour retirement date didn't move once - it moved slowly, then repeatedly, until the shift felt normal. That's ...Golden Portfolio | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cocrystal Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
